Incyte

FDA to quickly review Novartis’ capmatinib in rare lung cancer

https://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/

Incyte gets much-needed boost as eczema cream trial hits target

https://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

https://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/

Incyte’s JAK inhibitor for GVHD fails phase 3 trial

https://pharmaphorum.com/news/incytes-jak-inhibitor-for-gvhd-fails-phase-3-trial/

Incyte shares down sharply after phase 3 skin cancer trial failure

https://pharmaphorum.com/news/incyte-shares-down-sharply-after-phase-3-skin-cancer-trial-failure/

ASCO round up: Zytiga shines in frontline prostate role, Loxo and Incyte pass early tests

https://pharmaphorum.com/news/asco-data-points-zytiga/

Lilly slumps after FDA rejects RA pill

https://pharmaphorum.com/news/lilly-shares-slump-fda-rejects-ra-pill/

Incyte’s leukaemia drug Iclusig recommended by NICE

https://pharmaphorum.com/news/iclusig-nice-approval/

EU regulators back Lilly’s blockbuster RA pill

https://pharmaphorum.com/news/eu-regulators-back-lillys-blockbuster-ra-pill/

Close in 10 seconds

Pharmaphorum.com

Search